INTRODUCTION
============

The impact of environmental exposures on human health ranges from acute effects, such as skin irritation, to chronic long-term consequences, including cognitive and reproductive dysfunction. The life stage during which the exposure occurs has been deemed a critical determinant on the health consequences realized. The physiologic and metabolic characteristics of fetal development, including the immaturity of the blood--brain barrier and the reduced detoxification and elimination capacity of the internal organs such as liver and kidneys, mark the intrauterine experience as a period of heightened susceptibility \[[@R1]\]. In addition to impacting fetal development, environmental exposures can also modify the genome to program health outcomes experienced later in life. The molecular mechanism underlying this fetal programming, also referred to as the 'developmental origins of health and disease (DOHAD)' \[[@R2]\], has not been clearly delineated. However, mounting evidence suggests that epigenetics plays a vital role.

The epigenome refers to heritable, quasi-stable yet dynamic and environmentally responsive elements that regulate gene expression without changes in the DNA sequence itself \[[@R3]\]. Various epigenetic marks have been identified, including transcriptional regulation through DNA methylation and histone modification, as well as posttranscriptional regulation through microRNAs (miRNAs).

miRNAs are small noncoding RNAs, typically 21--23 nucleotides in length, formed from transcripts that take on a characteristic hairpin structure \[[@R4]\]. The process to generate miRNAs is initiated through the transcription of primary miRNA (pri-miRNA) by RNA polymerase II \[[@R5]\]. Processing by DROSHA, an RNAse III endonuclease, generates a 60--70-nt stem loop intermediate with a 3' overhang \[[@R6],[@R7]\]. This precursor miRNA (premRNA) is actively transported from the nucleus to the cytoplasm via Ran-GTP and Exportin-5, where it is further processed by an additional RNAse III endonuclease, DICER, into a double-stranded miRNA:miRNA∗ complex \[[@R8],[@R9],[@R10]\]. The mature single-stranded miRNA is loaded into the RNA-induced silencing complex (RISC), where it serves as a guide for targeting the RISC to mRNAs based on complementarity \[[@R11],[@R12]\]. The degree of complementarity between a miRNA and its targets determines the mechanism of posttranscriptional regulation. Near perfect pairing results in cleavage of the target mRNA, whereas partial pairing, a phenomenon more commonly observed in animals, results in either mRNA decay or translational repression \[[@R13]\].
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To date, over 2000 unique mature human miRNAs have been annotated and catalogued in the publicly accessible database miRBase ([www.miRbase.org](http://www.mirbase.org/)), and up to one-third of all mRNA transcripts are believed to be regulated by miRNAs \[[@R14]\]. As targeting only requires partial complementarity, a single miRNA can bind multiple mRNA transcripts and each mRNA can be bound to multiple miRNAs. In this way, miRNAs are able to modulate entire gene networks, including biological processes such as development, stem cell differentiation, hematopoiesis, cardiac/muscle development, neurogenesis, insulin secretion, cholesterol metabolism, and immune response \[[@R15]\]. Significant modifications in the expression of miRNAs likely result in the deregulation of these processes, ultimately triggering disease. Children are a population of special interest in determining the impact of miRNA deregulation as the heightened susceptibility to early life environmental exposures may play a role in modulating miRNA expression levels. Additionally, the downstream effects owing to the resulting deregulation of miRNAs are likely more pronounced as many of the miRNA-regulated physiologic processes are most active early in the developmental process. Hence, this review focuses on miRNAs as markers of in-utero environmental exposures and as candidates for the molecular basis through which these exposures exert their influence on children\'s health.

microRNA AND CHILDREN\'S HEALTH
===============================

A number of studies have implicated miRNAs in various pediatric health outcomes. As summarized in Table [1](#T1){ref-type="table"}, these studies showcase the wide-ranging utility of miRNAs as markers of disease, in terms of diagnosis, prognosis, disease subtype classification, treatment monitoring, and agents of intervention. However, greater understanding is also required in identifying the upstream elements capable of disrupting the expression profile of miRNAs, including environmental factors, ultimately resulting in disease.

microRNA AND THE IN-UTERO ENVIRONMENT
=====================================

Studies that have investigated the responsiveness of miRNAs to early life environmental exposures are summarized in Table [2](#T2){ref-type="table"}. The assessed exposures fall into three general categories: xenochemicals, endogenous agents, and nutrition. The group of xenochemicals includes ethanol and tobacco smoke, established teratogens known to cross the placenta and induce fetal malformation. The remaining chemicals in this group, including the endocrine disruptor bisphenol A, have suspected but not yet verified detrimental effects on normal human fetal development. Studies revolving around endogenous factors, including parental stress and hypoxia, indicate that miRNAs are responsive not only to exogenously introduced chemical exposures, but also to the dysregulation of the internal environment. Finally, nutrition is highlighted as its own distinct category, since the importance of the nutritional state in fetal development and programming has been previously established, the best-documented of which links fetal malnutrition with later onset of metabolic diseases in studies conducted on individuals exposed to the Dutch famine \[[@R55]\]. The following sections highlight findings from representative exposures in each category.

Tobacco smoke
-------------

Two human observational studies have been carried out to date assessing the role of miRNAs as potential mediators of the impact of tobacco smoke on in-utero development. Maccani *et al.*\[[@R46]\] compared the expression level of candidate miRNAs in 25 placentas obtained at the time of delivery from women with and without a history of smoking during pregnancy. Out of the four selected targets, a significant downregulation of miR-16, miR-21, and miR-146a was observed due to maternal cigarette smoking. Furthermore, miR-146a was significantly downregulated following exposure to both nicotine and benzopyrene in TCL-1 (immortalized human trophoblast cell line), a cell line derived from third trimester extravillous cells, whereas no impact due to either agent was observed on the remaining miRNAs.

The impact on miRNA expression levels due to tobacco smoke exposure during the gestational period was also addressed in a study conducted by Herberth *et al.*\[[@R47]\]. As this study was particularly concerned with the effect of tobacco smoke on immune-related responses, two candidate miRNAs, miR-155 and miR-223, previously implicated in Treg cell formation and function, were selected for analysis. In this prospective study of mother--child pairs, increasing levels of miR-223 were observed in both maternal and cord blood with increasing levels of cotinine in maternal urine.

Parental stress
---------------

In a study by Morgan and Bale \[[@R53]\], the impact of prenatal stress on brain development was assessed. For this purpose, the offspring of male mice that were prenatally exposed to maternal stressors were analyzed. Microarray analysis of brain-derived miRNAs revealed that the profile of F2 male offspring stemming from a stress-exposed lineage was more similar to the profile of nonexposed F2 female offspring than nonexposed F2 male offspring, suggesting dysmasculinization of the brain among the F2 stress-exposed males. Specifically, three miRNA species, miR-322, miR-574-3p, and miR-873, were observed to be downregulated among the F2 stress-exposed offspring, whereas the expression level of β-glycan, a predicted target common to all three miRNAs, was determined to be upregulated compared with F2 control offspring. Finally, following treatment with the aromatase inhibitor formestane, the brain miRNA profile of formestane-treated male mice clustered more closely to control female mice than control male mice, further suggesting that the miRNA environment is sensitive to hormonal dysregulation. The overall findings from this study, therefore, suggest that the changes incurred during in-utero development can be transmitted transgenerationally.

Nutrition
---------

The effects of a maternal high-fat diet on the miRNA profile of the resulting offspring were assessed in a murine model by Zhang *et al.*\[[@R54]\]. Microarray analysis of liver-derived miRNAs from female offspring identified 10 miRNAs that were upregulated and 23 miRNAs that were downregulated among offspring exposed to a high-fat diet. Although all targets were not successfully validated, the downregulation of miR-483∗ was consistently observed as the greatest fold-change among high-fat diet-exposed offspring. The authors determined that the genetic location of miR-483∗ lies within the intron of *Igf2,* a gene known to be critical in regulating fetal growth, indicating that the transcription of both is likely regulated by the same promoter. Paradoxically, among high fat-exposed mice, the downregulation of miR-483∗ was observed alongside an upregulation of *Igf2*.

FUTURE PERSPECTIVE
==================

Findings relaying the impact of in-utero exposures on miRNA expression levels thus far have raised several interesting questions that will need to be further addressed. Principal among these is determining whether the observed changes in miRNA expression levels reflect a causal pathway between exposure and outcome, identifying the downstream gene targets impacted by deregulated miRNAs, and delineating variability introduced because of methodological and biospecimen specifications.

Role of microRNAs in linking exposure to outcome
------------------------------------------------

To address this question, it will first have to be established whether the observed changes in miRNA expression levels due to environmental exposures are the result of a direct effect or a surrogate indication of a different mechanism. This issue was highlighted in the study by Herberth *et al.*, in which the expression level of miR-223 in blood was found to vary among different blood cell-types, leading the authors to question whether the observed tobacco-related increase in miR-223 levels is indeed a direct response to the exposure or a bystander effect of smoke-induced changes in blood cell-type composition \[[@R47]\]. Although the utility as a marker of exposure is not diminished in either case, the former would more directly associate miRNAs to the causal pathway linking exposures to putative deregulated physiological processes.

Given a substantiated impact of environmental exposures on miRNA expression levels and related physiological processes, more efforts into how these changes in expression profiles translate into health outcomes will also be warranted. To date, studies relating changes in miRNAs to various health outcomes and studies relating exposures to changes in miRNAs are often conducted separately. Few studies have linked the observed changes in miRNAs due to environmental exposures to known health effects. One such example includes the finding by Herberth *et al.*\[[@R47]\] that higher levels of miRNA-223 in cord blood were also correlated with decreasing levels of Treg cells in newborns, which in turn was shown to be associated with a significantly higher risk of developing atopic dermatitis by the age of 3. Such findings pave the way to further understand the etiologic processes underlying the exposure--outcome relationship and offer possibilities for remediation and intervention.

Prediction of microRNA targets
------------------------------

In order to identify potential physiological processes that are affected by the exposure-incurred changes in miRNA profiles, studies often employ various existing web-based programs (e.g., miRBase, Targetscan, PicTar) to identify putative mRNA targets of the aberrantly expressed miRNAs. Using slightly varying algorithms, these programs scan a library of mRNA 3'UTR regions to identify potential binding sites for the miRNAs of interest. However, as binding of miRNAs to their targets requires only partial complementarity, prediction of targets typically yields up to 20% false positives \[[@R56]\]. The substantial rate of false positives and the observed discrepancy in predicted targets across the various algorithms highlight the need to experimentally validate reported putative targets.

Methodological differences: next generation sequencing vs. microarray
---------------------------------------------------------------------

Several high-throughput methodologies are currently in use to determine miRNA expression levels. Utilization of microarrays relies on nucleic-acid hybridization of labeled miRNA-derived cDNAs to complementary oligonucleotide probes immobilized on the array, with fluorescence intensity indicating the level of expression. This methodology is currently the most widely applied means of high-throughput determination of miRNA expression levels. However, innate properties of miRNAs limit the sensitivity and specificity achieved with this method. For example, miRNAs of low abundance likely fall below the limit of detection on the array. There is also considerable sequence homology among miRNAs, which probes on the array may not be sensitive enough to distinguish. Next generation sequencing is a methodology that is able to address several of these limitations. Additionally, unlike array-based methods, profiles generated using sequencing are not limited to previously identified miRNAs. However, the multiple steps involved in setting up the sequencing reaction offer various opportunities to introduce bias \[[@R57]\]. Furthermore, although the price is continuously dropping, the cost of sequencing at present is still higher than array-based methods.

Specimen issues: placenta, cord blood, and maternal plasma
----------------------------------------------------------

As with any biomarker-related study, the biospecimen source of miRNAs greatly influences the interpretation of meaningful results. Placental tissue, umbilical cord blood, and maternal sera are common sources for biomarkers reflecting the in-utero experience in human observational studies. All three serve as easily obtainable, noninvasive sources of miRNAs. However, there are factors driving distinctions in the expression profile generated from these biospecimens that need to be considered. Both placenta and blood are composite tissues consisting of heterogeneous cell types. Therefore, minimizing variability in cell-type composition across samples needs to be accounted for prior to analysis to reduce the likelihood of introducing bias into the study. Cord blood does provide access to specific cell lineages that make this particular biospecimen an attractive source for studies focusing on the impact of environmental exposures on the differentiation potential of stem cell populations, such as neuronal precursors, and on the immune response of cytokines.

While the expression profile generated from placental tissue and cord blood reflects the exposure experience toward the end of pregnancy, maternal plasma offers a means to monitor dynamic changes in expression level throughout pregnancy, enabling the focus on specific gestational periods. However, the proportion of placental miRNA in circulation likely fails to account for the comprehensive expression profile of the placenta. Therefore, maternal plasma is best suited to develop screening markers, whereas cord blood and placental levels can also be analyzed to further etiologic understanding.

CONCLUSION
==========

The implementation of miRNAs as indicators of environmental exposures relevant to children\'s health is still a nascent field, and the promise of their utility is just beginning to be realized. While mRNA transcript levels, the ultimate targets of miRNAs, can also be utilized for this purpose, one of the major attractions over their labile transcript counterparts is the inherent stability and robustness of miRNAs in bodily fluids under various conditions \[[@R58],[@R59]\]. Furthermore, technological advances have made high-throughput assessment affordable, providing a means of feasible and sensitive detection.

The relevance of this marker in these types of studies is also established by the fact that miRNAs are known to be involved in processes with heightened activity during early development. Hence, beyond reflecting extent of exposure to an environmental agent, an observed deregulation of miRNA levels can also point to the etiologic mechanism, ultimately linking a given exposure to an outcome.

Already various exposure and outcome-related signatures have been identified. However, the lack of comparability in experimental conditions prevents deriving meaningful conclusions from the findings reported thus far. Even in studies focusing on the same exposure of interest, variability exists in the form of dosage, study population, biospecimen analyzed, detection methods utilized, and definitions for fold cut-offs. Hence, while technological advances yet to come will further facilitate the ability to assay and analyze expression profiles under various conditions, resulting in novel contributions to the literature, future studies should also focus on replicating existing expression profiles. Only by establishing reproducible expression profiles and validating putative gene targets can the ultimate goal of building a cohesive narrative tying environmental exposures to children\'s health outcomes be realized.
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###### 

Studies assessing microRNAs in pediatric health outcomes

  Outcome                            miRNA-related assessment                                                                Impact on outcome                                                                                                       Reference
  ---------------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Acute lymphocytic leukemia (ALL)   miRNA expression signature profile                                                      Diagnostic: case--control differences                                                                                   Schotte *et al.* 2009 \[[@R16]\]; Zhang *et al.* 2009 \[[@R17]\]; Oliveira *et al.* 2012 \[[@R18]\]
                                     miRNA expression signature profile                                                      Disease subtype classification: T-ALL/MLL vs. ALL                                                                       Schotte *et al.* 2009 \[[@R16]\]
                                     miRNA expression signature profile                                                      Disease subtype classification: T-ALL vs. B-ALL                                                                         Fulci *et al.* 2009 \[[@R19]\]
                                     miRNA expression signature profile                                                      Treatment monitoring: response to prednisone                                                                            Zhang *et al.* 2009 \[[@R17]\]
                                     miRNA expression signature profile                                                      Clinical prognosis                                                                                                      Zhang *et al.* 2009 \[[@R17]\]
                                     miRNA expression signature profile                                                      Clinical prognosis                                                                                                      Kaddar *et al.* 2009 \[[@R20]\]
  Asthma                             Presence of SNPs in HLA-G impacts miRNA binding to 3'UTR region                         Cause: Case--control difference                                                                                         Tan *et al.* 2007 \[[@R21]\]
                                     Presence of SNPs in miRNA genetic sequence                                              Cause: Case--control differences                                                                                        Su *et al.* 2011 \[[@R22]\]
                                     AntagomiR-targeted downregulation of miRNA                                              Intervention: reduces eosinic inflammation, mucus hypersecretion, TH2 cytokine production, airway hyperresponsiveness   Collison *et al.* 2011 \[[@R23]\]
  Autism                             miRNA expression signature profile                                                      Diagnostic: Case--control differences                                                                                   Abu-Elneel *et al.* 2008 \[[@R24]\]
                                     miRNA expression signature profile                                                      Diagnostic: Case--control differences                                                                                   Sarachana *et al.* 2010 \[[@R25]\]
                                     In-silico analysis                                                                      Etiology: miRNAs known to be deregulated in autism present in CNV loci                                                  Vaishnavi *et al.* 2013 \[[@R26]\]
  Congenital heart disease (CHD)     Presence of SNP in miRNA coding region                                                  Etiology: Case--control differences                                                                                     Xu *et al.* 2009 \[[@R27]\]
                                     In-silico analysis                                                                      Etiology: miRNAs present in CHD-related CNV loci                                                                        Xing *et al.* 2013 \[[@R28]\]
                                     miRNA expression signature profile                                                      Diagnostic: Case--control differences                                                                                   Zhu *et al.* 2013 \[[@R29]\]
  Cystic fibrosis                    miRNA expression signature profile                                                      Diagnostic: Case--control differences                                                                                   Oglesby *et al.* 2010 \[[@R30]\]
                                     In-silico/in-vitro analysis of CFTR 3'UTR binding targets                               Etiology: miRNAs regulate CFTR gene expression                                                                          Megiorni *et al.* 2011 \[[@R31]\]
                                     In-silico/in-vitro analysis of miRNAs and binding targets involved in CFTR regulation   Treatment: restore function of mutated CFTR protein                                                                     Ramachandran *et al.* 2012 \[[@R32]\]
                                     miRNAs involved in CFTR regulation                                                      Cause: miRNAs regulate CFTR gene expression                                                                             Oglesby *et al.* 2013 \[[@R33]\]
                                     In-vitro analysis: biogenesis and maturation of candidate miRNA                         Cause: RNA binding proteins regulate maturation of miRNA upregulated in CF                                              Bhattacharyya *et al.* 2013 \[[@R34]\]
  Diabetes, Type 1 (T1D)             Candidate miRNA expression analysis                                                     Clinical prognosis                                                                                                      Sebastiani *et al.* 2011 \[[@R35]\]
                                     miRNA expression signature profile                                                      Diagnostic: Case--control differences                                                                                   Nielsen *et al.* 2012 \[[@R36]\]
                                     Candidate miRNA expression analysis                                                     Diagnostic: Case--control differences                                                                                   Salas-Pérez *et al.* 2013 \[[@R37]\]
  Neuroblastoma                      miRNA expression signature profile                                                      Disease subtype classification                                                                                          Chen and Stallings, 2007 \[[@R38]\]
                                     miRNA expression signature profile                                                      Clinical prognosis                                                                                                      Bray *et al.* 2009 \[[@R39]\]
  Obesity                            miRNA expression signature profile                                                      Diagnostic: miRNA expression pattern associated with obesity markers                                                    Prats-Puig *et al.* 2013 \[[@R40]\]

3' UTR, 3' untranslated region; ALL, acute lymphoblastic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CHD, chronic heart disease; CNV, copy number variation; HLA-G, human leukocyte antigen G; miRNA, microRNA; MLL, mixed lineage leukemia; SNP, single nucleotide polymorphism; T-ALL, T-cell acute lymphoblastic leukemia; TH2, Type 2 helper cells.

###### 

Impact of in-utero environmental exposures on microRNA expression levels

  Environmental agent   miRNA         Target gene/pathway          Function                                                    Species     Biospecimen/cell type                  Reference
  --------------------- ------------- ---------------------------- ----------------------------------------------------------- ----------- -------------------------------------- ------------------------------------------
  Xenochemical                                                                                                                                                                    
   BPA                  miR-146a                                   TLR/cytokine signaling                                      Human       Placenta cell line                     Avissar-Whiting *et al.* 2010 \[[@R41]\]
   Ethanol              miR-21        *Jag-1*                      Notch ligand/proliferation of neuroepithelial cells         Mouse       Cerebral cortex-derived neurospheres   Sathyan *et al.* 2007 \[[@R42]\]
                        miR-335       *Ela Vl2*                    Promotes neuronal maturation                                                                                   
                        miR-9                                                                                                                                                     
                        miR-153                                                                                                                                                   
                        miR-10a       *HOXa1*                                                                                  Mouse       Brain                                  Wang *et al.* 2009 \[[@R43]\]
                        miR-10b                                                                                                                                                   
                        miR-9                                                                                                                                                     
                        miR-145                                                                                                                                                   
                        miR-153a      *Pou4f1*                     Regulation of transcription                                 Zebrafish   Embryo                                 Soares *et al.* 2012 \[[@R44]\]
                        miR-30d       *Pou4f1*                                                                                                                                    
                        miR-725                                                                                                                                                   
                        let7k                                                                                                                                                     
                        miR-100                                                                                                                                                   
                        miR-738                                                                                                                                                   
                        miR-732                                                                                                                                                   
   Gold nanoparticles   let-7a                                     Cell proliferation                                          Mouse       Liver and lung                         Balansky *et al.* 2013 \[[@R45]\]
                                                                   k-RAS activation                                                                                               
                                                                   Apoptosis                                                                                                      
                        miR-183                                    Apoptosis                                                                                                      
                                                                   Cell adhesion                                                                                                  
   Maternal smoking     miR-146a      *BCL2L2*/*EDA*               Pro-survival                                                Human       Placenta                               Maccani *et al.* 2010 \[[@R46]\]
                                                                   NF-κβ pathway                                                                                                  
                        miR-16        *PLAG1*/ *SATB1*             Cell cycle/cell proliferation transcription factors                                                            
                        miR-21        *TRAF6*                      NF-κβ/TLR4 pathway                                                                                             
                        miR-223                                    Progenitor cell proliferation/granulocyte differentiation   Human       Cord blood                             Herberth *et al.* 2013 \[[@R47]\]
   PCBs                 miR-762       *Wnt1*                       Cardiovascular differentiation                              Mouse       P19 cells embryonal carcinoma          Zhu *et al.* 2012 \[[@R48]\]
                        miR-29a       *Gsk3β*                      Cardiovascular differentiation                                                                                 
                                                                                                                                                                                  
                        miR-324-      *Nkx2.5*                     Heart development                                                                                              
                        5p                                                                                                                                                        
   PFOS                 miR-19b-c     *Cdk5 Smad1 Sox11b Pou5f1*   Brain and nervous system development                        Zebrafish   Embryo                                 Zhang *et al.* 2011 \[[@R49]\]
                                      *Bax*                        Apoptosis                                                                                                      
                                      *Vsx1*                                                                                                                                      
                        miR-19d                                                                                                                                                   
                        miR-181b-c                                                                                                                                                
                        miR-735                                                                                                                                                   
                        miR-739                                                                                                                                                   
                        miR-297       *Ypel5*                                                                                  Rat         Brain                                  Wang *et al*. 2012 \[[@R50]\]
                        miR-672       *Fgfr3*                                                                                                                                     
                                      *Syt1*                                                                                                                                      
   TCDD                 mir-122                                    Metabolism                                                  Mouse       Thymus                                 Singh *et al.* 2012 \[[@R51]\]
                        miR-181a                                   T-cell sensitivity and selection                                                                               
                        miR-23a       *Fas*                        Apoptosis                                                                                                      
                        miR-18b       *FasL*                       Apoptosis                                                                                                      
                        miR-31        *Cyp1a1*                     Metabolism                                                                                                     
                        miR-182       *AhR*                        Metabolism                                                                                                     
  Endogenous factor                                                                                                                                                               
   Hypoxia              mR-520c-3p                                                                                             Human       Placenta                               Donker *et al.* 2012 \[[@R52]\]
   Paternal stress      miR-322       *β-glycan*                   TGF superfamily                                             Mouse       Brain                                  Morgan *et al.* 2011 \[[@R53]\]
                        miR-574-3p                                                                                                                                                
                        miR-873                                                                                                                                                   
  Nutrition                                                                                                                                                                       
   High-fat diet        miR-483^\*^   *Zswim3*                                                                                 Mouse       Liver                                  Zhang *et al.* 2009 \[[@R54]\]

AhR, aryl hydrocarbon receptor; BAX, BCL2-associated X protein; BCL2L2, BCL2-like 2; BPA, bisphenol A; CDK5, cyclin-dependent kinase 5; CYP1A1, cytochrome P450, family 1, subfamily A, polypeptide 1; EDA, ectodysplasin A; ELAVL2, ELAV-like neuron-specific RNA binding protein 2; Fas, Fas cell surface death receptor; FasL, Fas ligand; GSK3B, glycogen synthase kinase 3 beta; HOXa1, homeobox A1; Jag-1, jagged 1; k-RAS, Kirsten rat sarcoma viral oncogene homolog; NFkB, nuclear factor kappa B; NKX2.5, NK2 homeobox 5; PCBs, polychlorinated biphenyls; PFOS, perfluorooctane sulfonate; PLAG1, pleiomorphic adenoma gene 1; Pou4f1, POU class 4 homeobox 1; Pou5f1, POU class 5 homeobox 1; SATB1, SATB homeobox 1; Smad1, SMAD family member 1; Sox11b, SRY-box containing gene 11b; TCDD, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin; TGF, transcription growth factor; TLR, Toll-like receptor; TLR4, Toll-like receptor 4; TRAF6, TNF receptor-associated factor 6; Vsx1, visual system homeobox 1; Wnt1, wingless-type MMTV integration site family, member 1; ZSWIM3, zinc finger, SWIM-type containing 3.
